Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone561-743-8333
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$760,000.00
Profitability
Miscellaneous
Employees6
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Dyadic International (NASDAQ:DYAI) Frequently Asked Questions
What is Dyadic International's stock symbol?
Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."
How were Dyadic International's earnings last quarter?
Dyadic International, Inc (NASDAQ:DYAI) announced its earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.03. The biotechnology company had revenue of $0.39 million for the quarter, compared to analyst estimates of $0.40 million. View Dyadic International's Earnings History.
When is Dyadic International's next earnings date?
What price target have analysts set for DYAI?
1 equities research analysts have issued 12 month target prices for Dyadic International's shares. Their forecasts range from $9.00 to $9.00. On average, they expect Dyadic International's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price. View Analyst Price Targets for Dyadic International.
What is the consensus analysts' recommendation for Dyadic International?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dyadic International.
Has Dyadic International been receiving favorable news coverage?
Press coverage about DYAI stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Dyadic International earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Dyadic International.
Are investors shorting Dyadic International?
Dyadic International saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 555,200 shares, an increase of 27.9% from the August 30th total of 434,100 shares. Based on an average trading volume of 99,300 shares, the days-to-cover ratio is currently 5.6 days. Approximately 3.0% of the shares of the stock are short sold. View Dyadic International's Current Options Chain.
Who are some of Dyadic International's key competitors?
Some companies that are related to Dyadic International include Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Krystal Biotech (KRYS), Osiris Therapeutics (OSIR), AVITA MED LTD/S (RCEL), Vericel (VCEL), Cortexyme (CRTX), Mesoblast (MESO), AVITA MED LTD/S (AVMXY), Voyager Therapeutics (VYGR), GENFIT S A/ADR (GNFT), Autolus Therapeutics (AUTL), Solid Biosciences (SLDB), MeiraGTx (MGTX) and DBV TECHNOLOGIE/S (DBVT).
What other stocks do shareholders of Dyadic International own?
Who are Dyadic International's key executives?
Dyadic International's management team includes the folowing people:
- Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 63)
- Ms. Ping Wang Rawson, Chief Accounting Officer & Principal Financial Officer (Age 43)
- Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 41)
- Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 61)
- Ms. Ana Gómez Rodriguez, Sec. of the Board
Who are Dyadic International's major shareholders?
Which institutional investors are buying Dyadic International stock?
How do I buy shares of Dyadic International?
Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dyadic International's stock price today?
One share of DYAI stock can currently be purchased for approximately $6.64.
How big of a company is Dyadic International?
What is Dyadic International's official website?
How can I contact Dyadic International?
Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected]
MarketBeat Community Rating for Dyadic International (NASDAQ DYAI)
MarketBeat's community ratings are surveys of what our community members think about Dyadic International and other stocks. Vote "Outperform" if you believe DYAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
